Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.40 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.40 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113075 | 0.90 | MET (0.46) | HPGDP2RX4METSLC6A9LMNA | |
| SCHEMBL5099764 | 0.90 | MET (0.46) | P2RX4METSLC6A9LMNAMRGPRX4 | |
| SCHEMBL7126958 | 0.89 | MET (0.46) | P2RX4METSLC6A9LMNANPC1 | |
| SCHEMBL7124454 | 0.88 | MET (0.45) | P2RX4METSLC6A9LMNAMRGPRX4 | |
| SCHEMBL6554651 | 0.84 | HPGD (0.45) | HPGDMETSLC6A9MRGPRX4NPC1 | |
| SCHEMBL5093181 | 0.82 | SLC6A9 (0.45) | METSLC6A9MRGPRX4NPC1RAB9A | |
| SCHEMBL7127088 | 0.79 | MRGPRX4 (0.49) | P2RX4METLMNAMRGPRX4PPIA | |
| SCHEMBL7121876 | 0.79 | ALDH1A1 (0.49) | P2RX4LMNA | |
| SCHEMBL7117549 | 0.77 | SPHK1 (0.47) | P2RX4METLMNAMRGPRX4 | |
| SCHEMBL7160217 | 0.77 | P2RX4 (0.44) | HPGDP2RX4METNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | HPGD 1175/4885POLB 3255/4885P2RX4 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.